TCL1A antibody (PE)

Catalog No. ABIN2663891

Product Details anti-TCL1A Antibody (PE)

Target: TCL1A (T-Cell Leukemia/lymphoma 1A (TCL1A))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TCL1A antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: 1-21

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TCL1A

Target: TCL1A (T-Cell Leukemia/lymphoma 1A (TCL1A))

Alternative Name: TCL1 (TCL1A Products)

Synonyms: TCL1A antibody, Tcl1a antibody, TCL1 antibody, Tcl1 antibody, T-cell leukemia/lymphoma 1A antibody, T cell lymphoma breakpoint 1 antibody, TCL1A antibody, Tcl1 antibody, Tcl1a antibody

Background: TCL1, also known as T-cell leukemia/lymphoma protein 1A, protein p14 TCL1 and oncogene TCL-1, is a 14kD beta-barrel protein that was originally identified on the basis of its association with T-cell prolymphocytic leukemia (T-PLL). Activated by the T-cell receptor enhancer through inv(14)(q11,q32.1) or t(14,14)(q11,q32.1), TCL1 is normally expressed in immature cortical thymocytes, activated peripheral T-cells, pro-B cells, and naive mantle zone B cells of peripheral lymphoid tissues, but not in post-germinal center (GC) memory B cells and plasma cells. Akt and TCL1 interact via Akt's pleckstrin homology domain to form hetero-oligomers at the leaflet of the inner plasma membrane stimulating the protein kinase C-mitogen activated protein kinase-extracellular signal-related kinase (PKC-MAPK-ERK) signal transduction pathway. TCL1 also inhibits activation-induced cell death in T-cells by blocking PKCθ. In addition to T-PLL dysregulation is implicated in such B-cell neoplasias as lymphoblastic lymphoma, chronic lymphocytic leukemia (CLL) and Burkitt lymphoma.

Pathways: Stem Cell Maintenance